cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.xrhhce
title: Occurrence Download

description: A dataset containing 65 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Sarotherodon galilaeus",
 "Country is Israel",
 "HasCoordinate is true"
 ]
}

 The dataset includes 65 records from 16 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032211-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pvd92t
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Sarotherodon galilaeus",
 "Country is South Africa",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032213-250920141307145/datasets/export for details.
DOI: 10.7910/dvn/8mpsuq
title: University of KwaZulu-Natal 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.

description: University of KwaZulu-Natal 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.
description: University of KwaZulu-Natal 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.
DOI: 10.15468/dl.8zxake
title: Occurrence Download

description: A dataset containing 111 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Pterocles orientalis"
 ]
}

 The dataset includes 111 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032214-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7910/dvn/cp5goq
title: University of Limpopo 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.

description: University of Limpopo 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.
description: University of Limpopo 2025/2026 Undergraduate Form, Diploma Form Is On Sales! Call Admin Via WhatsApp +27780430015‬ To Apply Contact The Registrar Office Via WhatsApp ‪(+27780430015) ‪(+27780430015) For Guidelines On How To Apply And Register Before Closing Date! Registrar Office Via WhatsApp ‪+27780430015.
DOI: 10.15468/dl.5sk8y8
title: Occurrence Download

description: A dataset containing 32998 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Aves de las Reservas Distritales de Humedal de Bogotá, D.C."
 ]
}

 The dataset includes 32998 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032215-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hc4zp7
title: Occurrence Download

description: A dataset containing 351 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Chlosyne lacinia saundersi"
 ]
}

 The dataset includes 351 records from 19 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032216-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30240487
title: Supplementary Material for: Ponatinib Monotherapy in adult patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including MRD Relapse

description: Introduction: The treatment of relapsed or refractory (R/R) Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) remains challenging after failure to several tyrosine kinase inhibitors. This study evaluated the clinical outcomes of ponatinib in a real-world cohort with R/R Ph-positive ALL, including those treated at the stage of measurable residual disease (MRD) relapse.

Methods: We retrospectively analyzed 79 adults with R/R Ph-positive ALL treated with ponatinib monotherapy. At the start of treatment, 55 patients (69.6%) were in hematologic relapse, while 24 (30.4%) were in MRD relapse. We evaluated CR rate, MRD response, survival outcomes, and predictors of response and survival according to various clinical and genetic parameters.

Results: CR was achieved in 48 (60.7%) patients, and 22 of 46 with MRD data (47.8%) achieved CMR. Ponatinib initiation at MRD relapse was associated with higher odds of better molecular response. In multivariate analysis, age under 60 and MRD response better than MMR were linked to improved OS. However, 2-year OS remained poor at 29.5% (95% CI: 18.9–40.9%). Allo-HCT was performed in 38 patients (48.1%), with a 2-year post-transplant OS of 29.1% (95% CI: 12.9–47.6%). Prior allo-HCT was associated with inferior OS and DFS.

Conclusion: Ponatinib achieved an acceptable CR rate and MRD response in R/R Ph-positive ALL, but long-term survival remained poor despite allo-HCT. These results support earlier use of ponatinib in the salvage setting and highlight the need for combination strategies to overcome the limited durability of monotherapy in patients with R/R Ph-positive ALL.
DOI: 10.6084/m9.figshare.30240487.v1
title: Supplementary Material for: Ponatinib Monotherapy in adult patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including MRD Relapse

description: Introduction: The treatment of relapsed or refractory (R/R) Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) remains challenging after failure to several tyrosine kinase inhibitors. This study evaluated the clinical outcomes of ponatinib in a real-world cohort with R/R Ph-positive ALL, including those treated at the stage of measurable residual disease (MRD) relapse.

Methods: We retrospectively analyzed 79 adults with R/R Ph-positive ALL treated with ponatinib monotherapy. At the start of treatment, 55 patients (69.6%) were in hematologic relapse, while 24 (30.4%) were in MRD relapse. We evaluated CR rate, MRD response, survival outcomes, and predictors of response and survival according to various clinical and genetic parameters.

Results: CR was achieved in 48 (60.7%) patients, and 22 of 46 with MRD data (47.8%) achieved CMR. Ponatinib initiation at MRD relapse was associated with higher odds of better molecular response. In multivariate analysis, age under 60 and MRD response better than MMR were linked to improved OS. However, 2-year OS remained poor at 29.5% (95% CI: 18.9–40.9%). Allo-HCT was performed in 38 patients (48.1%), with a 2-year post-transplant OS of 29.1% (95% CI: 12.9–47.6%). Prior allo-HCT was associated with inferior OS and DFS.

Conclusion: Ponatinib achieved an acceptable CR rate and MRD response in R/R Ph-positive ALL, but long-term survival remained poor despite allo-HCT. These results support earlier use of ponatinib in the salvage setting and highlight the need for combination strategies to overcome the limited durability of monotherapy in patients with R/R Ph-positive ALL.
DOI: 10.15468/dl.4apm64
title: Occurrence Download

description: A dataset containing 868 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Physcomitrium eurystomum"
 ]
}

 The dataset includes 868 records from 98 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032217-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30240490
title: Supplementary Material for: Sodergren score translation and validation for hemorrhoidal disease in a Portuguese cohort

description: Aim: This study aimed to validate the Sodergren Score (SS) in the Portuguese population and develop a new model incorporating symptoms and quality-of-life variables.
Methods: A single-center, cross-sectional study, conducted in patients diagnosed with grade I-III hemorrhoidal disease (HD) by gastroenterologists specialized in proctology, between January and December 2023. The SS was translated and validated into Portuguese. Patients completed the Portuguese version of the SS and the EUROHIS-QOL-8. Demographic and clinical data were collected. The SS was validated using ROC curve analysis for identification of failure of office-based treatments (OBT), defined as the need for ≥ 4 OBT. Additionally, based on SS variables, a new model (Amadora-Sintra) was developed, combining symptom and quality-of-life variables. 
Results: We included 87 patients, 51.7% females and with mean age of 59 years-old [27-87]. At the time of questionnaire collection, patients reported a median of 3 symptoms and prolapse was the most common (85.1%). On proctological examination, most of the patients presented HD Goligher grade II (75.9%). The median SS and EUROHIS-QOL-8 score were 3.0 and 3.5, respectively. The SS identified patients needing ≥ 4 OBT with an AUC = 0.719 (95% CI: [0.61-0.83]) at a cut-off of ≥3 (sensitivity 0.85, specificity 0.47). The Amadora-Sintra model showed superior performance with an AUC = 0.778 (95% CI: [0.66-0.90]), cut-off ≥ 0.105 (sensitivity 0.85, specificity 0.55).
Conclusions: Both the SS and Amadora-Sintra models performed well in identifying patients who didn’t respond to OBT and consequently needed surgery, with the new model standing out for higher performance.
DOI: 10.6084/m9.figshare.30240490.v1
title: Supplementary Material for: Sodergren score translation and validation for hemorrhoidal disease in a Portuguese cohort

description: Aim: This study aimed to validate the Sodergren Score (SS) in the Portuguese population and develop a new model incorporating symptoms and quality-of-life variables.
Methods: A single-center, cross-sectional study, conducted in patients diagnosed with grade I-III hemorrhoidal disease (HD) by gastroenterologists specialized in proctology, between January and December 2023. The SS was translated and validated into Portuguese. Patients completed the Portuguese version of the SS and the EUROHIS-QOL-8. Demographic and clinical data were collected. The SS was validated using ROC curve analysis for identification of failure of office-based treatments (OBT), defined as the need for ≥ 4 OBT. Additionally, based on SS variables, a new model (Amadora-Sintra) was developed, combining symptom and quality-of-life variables. 
Results: We included 87 patients, 51.7% females and with mean age of 59 years-old [27-87]. At the time of questionnaire collection, patients reported a median of 3 symptoms and prolapse was the most common (85.1%). On proctological examination, most of the patients presented HD Goligher grade II (75.9%). The median SS and EUROHIS-QOL-8 score were 3.0 and 3.5, respectively. The SS identified patients needing ≥ 4 OBT with an AUC = 0.719 (95% CI: [0.61-0.83]) at a cut-off of ≥3 (sensitivity 0.85, specificity 0.47). The Amadora-Sintra model showed superior performance with an AUC = 0.778 (95% CI: [0.66-0.90]), cut-off ≥ 0.105 (sensitivity 0.85, specificity 0.55).
Conclusions: Both the SS and Amadora-Sintra models performed well in identifying patients who didn’t respond to OBT and consequently needed surgery, with the new model standing out for higher performance.
DOI: 10.6084/m9.figshare.30240493
title: Supplementary Material for: Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study

description: Introduction 
Renal anemia, a common complication of chronic kidney disease (CKD), is traditionally managed with erythropoiesis-stimulating agents (ESAs), which carry cardiovascular risks. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), offers a novel mechanism by enhancing erythropoietin production and iron metabolism. While randomized controlled trials (RCTs) demonstrate its efficacy, real-world data (RWD) on long-term safety and effectiveness remain limited.

Methods
This retrospective study analyzed 6,414 hemodialysis patients with renal anemia from a single center (December 2018–December 2023), comparing roxadustat (n=3,184) and ESA (n=3,230) groups. Propensity score matching was used to balance the baseline characteristics. Efficacy outcomes included hemoglobin (Hb) changes (baseline to months 6–12 and 18–30) and Hb response rates. Safety endpoints assessed major adverse cardiovascular events (MACE), heart failure hospitalization (HHF), thromboembolism, and all-cause mortality. Sensitivity analyses addressed treatment crossover and confounding.

Results
Roxadustat showed significantly greater Hb increases versus ESA at 6–12 months (LSM difference: 0.46 g/dL, p=0.04) and 18–30 months (0.26 g/dL, p=0.01). Hb response rates were higher with roxadustat (84.0% vs. 76%, p&lt;0.01). No significant differences were observed in MACE (HR 1.08, p=0.12), HHF (HR 0.88, p=0.25), thromboembolism (HR 1.05, p=0.34), or mortality (HR 0.94, p=0.29). Subgroup analyses suggested that roxadustat elevated MACE risk in patients with baseline hypertension or cardiovascular history, but sensitivity analyses nullified this association.

Conclusion
Roxadustat demonstrated superior efficacy in elevating and sustaining Hb levels compared to ESA over a longer observation period, with comparable cardiovascular safety in hemodialysis-dependent CKD patients. Roxadustat represents a viable alternative to ESA for renal anemia management, though long-term multicenter studies are needed to validate safety and optimize clinical use.
DOI: 10.6084/m9.figshare.30240493.v1
title: Supplementary Material for: Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study

description: Introduction 
Renal anemia, a common complication of chronic kidney disease (CKD), is traditionally managed with erythropoiesis-stimulating agents (ESAs), which carry cardiovascular risks. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), offers a novel mechanism by enhancing erythropoietin production and iron metabolism. While randomized controlled trials (RCTs) demonstrate its efficacy, real-world data (RWD) on long-term safety and effectiveness remain limited.

Methods
This retrospective study analyzed 6,414 hemodialysis patients with renal anemia from a single center (December 2018–December 2023), comparing roxadustat (n=3,184) and ESA (n=3,230) groups. Propensity score matching was used to balance the baseline characteristics. Efficacy outcomes included hemoglobin (Hb) changes (baseline to months 6–12 and 18–30) and Hb response rates. Safety endpoints assessed major adverse cardiovascular events (MACE), heart failure hospitalization (HHF), thromboembolism, and all-cause mortality. Sensitivity analyses addressed treatment crossover and confounding.

Results
Roxadustat showed significantly greater Hb increases versus ESA at 6–12 months (LSM difference: 0.46 g/dL, p=0.04) and 18–30 months (0.26 g/dL, p=0.01). Hb response rates were higher with roxadustat (84.0% vs. 76%, p&lt;0.01). No significant differences were observed in MACE (HR 1.08, p=0.12), HHF (HR 0.88, p=0.25), thromboembolism (HR 1.05, p=0.34), or mortality (HR 0.94, p=0.29). Subgroup analyses suggested that roxadustat elevated MACE risk in patients with baseline hypertension or cardiovascular history, but sensitivity analyses nullified this association.

Conclusion
Roxadustat demonstrated superior efficacy in elevating and sustaining Hb levels compared to ESA over a longer observation period, with comparable cardiovascular safety in hemodialysis-dependent CKD patients. Roxadustat represents a viable alternative to ESA for renal anemia management, though long-term multicenter studies are needed to validate safety and optimize clinical use.
DOI: 10.15468/dl.xdbnzy
title: Occurrence Download

description: A dataset containing 21 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Eleotris oxycephala",
 "Country is China",
 "HasCoordinate is true"
 ]
}

 The dataset includes 21 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032218-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30240496
title: Supplementary Material for: Diagnostic accuracy of cholangioscopy in the investigation of undetermined biliary stenosis – a retrospective study of an high volume ERCP center

description: Introduction: An indeterminate biliary stricture poses a difficult diagnostic and therapeutic challenge for both Gastroenterologists and Surgeons. It is estimated that 25% of patients submitted to surgery because of suspected malignant stricture have no evidence of malignancy tissue in the evaluation of the surgical specimens. Single-operator cholangioscopy enables the direct visualization of the biliary tree and the acquisition of histologic material through guided biopsies. 
Methods: Retrospective study from a prospective database of patients submitted to cholangioscopy for indeterminate biliary stricture, defined as the evidence of a narrowing of the biliary tree on imaging that remained undiagnosed after the collection of histologic material by ERCP with brush cytology. We calculated the values of sensitivity (S), specificity (SP), negative predictive value (NPV) and positive predictive values (PPV) of both the optical diagnosis and histological diagnosis.
Results: Sample of 47 patients. For the optical diagnosis, we obtained the following results: S = 94.4%; SP = 89.7%; NPV = 96.3%; PPV = 85.0%. For the cholangioscopy-guided biopsies, we obtained the following results: S = 64.7%; SP = 100.0%; NPV = 77.8%; PPV = 100.0%. 
Discussion: Cholangioscopy appears to be a safe and effective method in the distinction between benign and malignant biliary strictures. The distal location of the stricture did not appear to negatively influence the diagnostic yield of cholangioscopy.
DOI: 10.6084/m9.figshare.30240496.v1
title: Supplementary Material for: Diagnostic accuracy of cholangioscopy in the investigation of undetermined biliary stenosis – a retrospective study of an high volume ERCP center

description: Introduction: An indeterminate biliary stricture poses a difficult diagnostic and therapeutic challenge for both Gastroenterologists and Surgeons. It is estimated that 25% of patients submitted to surgery because of suspected malignant stricture have no evidence of malignancy tissue in the evaluation of the surgical specimens. Single-operator cholangioscopy enables the direct visualization of the biliary tree and the acquisition of histologic material through guided biopsies. 
Methods: Retrospective study from a prospective database of patients submitted to cholangioscopy for indeterminate biliary stricture, defined as the evidence of a narrowing of the biliary tree on imaging that remained undiagnosed after the collection of histologic material by ERCP with brush cytology. We calculated the values of sensitivity (S), specificity (SP), negative predictive value (NPV) and positive predictive values (PPV) of both the optical diagnosis and histological diagnosis.
Results: Sample of 47 patients. For the optical diagnosis, we obtained the following results: S = 94.4%; SP = 89.7%; NPV = 96.3%; PPV = 85.0%. For the cholangioscopy-guided biopsies, we obtained the following results: S = 64.7%; SP = 100.0%; NPV = 77.8%; PPV = 100.0%. 
Discussion: Cholangioscopy appears to be a safe and effective method in the distinction between benign and malignant biliary strictures. The distal location of the stricture did not appear to negatively influence the diagnostic yield of cholangioscopy.
DOI: 10.6084/m9.figshare.30240502
title: Supplementary Material for: Soluble interleukin-1 receptor type 2 (sIL-1R2) as a marker of inflammation and disease severity in patients with cirrhosis

description: Introdution: Cirrhosis involves immune dysfunction and systemic inflammation, especially during acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Soluble interleukin-1 receptor type 2 (sIL-1R2) acts as a decoy receptor for IL-1β with anti-inflammatory effects, but its role in cirrhosis is unclear. Our aim was to assess serum sIL-1R2 levels in patients with cirrhosis, compare them across disease stages and healthy controls, and examine associations with inflammation, bacterial infection, organ failure, and short-term mortality. Methods: We studied 240 individuals: 200 hospitalized with AD, 20 with stable cirrhosis, and 20 healthy controls. Serum sIL-1R2 was measured by ELISA. Clinical data, infection, organ failure, and 30-day outcomes were analyzed using Cox regression and Kaplan-Meier methods. Results: sIL-1R2 levels were significantly higher in AD patients than in stable cirrhotics or controls (p &lt; 0.05). Levels correlated with leukocyte and neutrophil counts, liver function scores (Child-Pugh, MELD, CLIF-SOFA), and were elevated in cases of liver and coagulation failure. Among infected patients, the Kaplan-Meier survival probability was 81.6% in sIL-1R2 &lt; 8300 pg/mL and 57.1% in values ≥ 8300 pg/mL (p = 0.009). Conclusions: Serum sIL-1R2 increases with cirrhosis severity and may reflect inflammation and organ failure. It may serve as a short-term prognostic biomarker in infected patients.